Daniel J Lovell

Summary

Affiliation: Cincinnati Children's Hospital Medical Center
Country: USA

Publications

  1. pmc Safety of celecoxib and nonselective nonsteroidal anti-inflammatory drugs in juvenile idiopathic arthritis: results of the Phase 4 registry
    Rachel E Sobel
    Pfizer Inc, 235 East 42nd St, MS 219 9 1, New York, NY 10017, USA
    Pediatr Rheumatol Online J 12:29. 2014
  2. doi request reprint Advances from clinical trials in juvenile idiopathic arthritis
    Daniel J Lovell
    Cincinnati Children s Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH 45229, USA
    Nat Rev Rheumatol 9:557-63. 2013
  3. pmc Summary of worldwide pediatric malignancies reported after exposure to etanercept
    Peter McCroskery
    Amgen Inc, Thousand Oaks, CA, Seattle WA, and South San Francisco, CA, USA
    Pediatr Rheumatol Online J 8:18. 2010
  4. ncbi request reprint Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial
    Daniel J Lovell
    Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio 45229 3039, USA
    Arthritis Rheum 48:218-26. 2003
  5. doi request reprint Adalimumab with or without methotrexate in juvenile rheumatoid arthritis
    Daniel J Lovell
    Cincinnati Children s Hospital Medical Center, Division of Rheumatology, Location E, Rm 2 129, MLC 4010, 3333 Burnet Ave, Cincinnati, OH 45229 3039, USA
    N Engl J Med 359:810-20. 2008
  6. ncbi request reprint Biologic agents for the treatment of juvenile rheumatoid arthritis: current status
    Ruy Carrasco
    Levinson Chair of Pediatric Rheumatology, Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio 45229, USA
    Paediatr Drugs 6:137-46. 2004
  7. doi request reprint Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis
    Daniel J Lovell
    Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio 45229, USA
    Arthritis Rheum 58:1496-504. 2008
  8. pmc Measuring process of arthritis care: a proposed set of quality measures for the process of care in juvenile idiopathic arthritis
    Daniel J Lovell
    Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio 45229, USA
    Arthritis Care Res (Hoboken) 63:10-6. 2011
  9. ncbi request reprint A randomized controlled trial of calcium supplementation to increase bone mineral density in children with juvenile rheumatoid arthritis
    Daniel J Lovell
    Cincinnati Children s Hospital Medical Center, William S Rowe Division of Rheumatology ML4010, 3333 Burnet Avenue, Cincinnati, OH 45229, USA
    Arthritis Rheum 54:2235-42. 2006
  10. ncbi request reprint Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal-onset multisystem inflammatory disease
    Daniel J Lovell
    Cincinnati Children s Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio 45229, USA
    Arthritis Rheum 52:1283-6. 2005

Research Grants

  1. CLINICAL TRAILS IN PEDIATRIC RHEUMATOLOGY
    Daniel Lovell; Fiscal Year: 2004

Detail Information

Publications55

  1. pmc Safety of celecoxib and nonselective nonsteroidal anti-inflammatory drugs in juvenile idiopathic arthritis: results of the Phase 4 registry
    Rachel E Sobel
    Pfizer Inc, 235 East 42nd St, MS 219 9 1, New York, NY 10017, USA
    Pediatr Rheumatol Online J 12:29. 2014
    ..This study aimed to assess long-term safety and developmental data on juvenile idiopathic arthritis (JIA) patients treated in routine clinical practice with celecoxib or nonselective nonsteroidal anti-inflammatory drugs (nsNSAIDs)...
  2. doi request reprint Advances from clinical trials in juvenile idiopathic arthritis
    Daniel J Lovell
    Cincinnati Children s Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH 45229, USA
    Nat Rev Rheumatol 9:557-63. 2013
    ....
  3. pmc Summary of worldwide pediatric malignancies reported after exposure to etanercept
    Peter McCroskery
    Amgen Inc, Thousand Oaks, CA, Seattle WA, and South San Francisco, CA, USA
    Pediatr Rheumatol Online J 8:18. 2010
    ..We examined the worldwide experience of etanercept use in pediatric patients and the occurrence of malignancies as reported from clinical trials, registry studies, post-marketing surveillance, and published scientific literature...
  4. ncbi request reprint Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial
    Daniel J Lovell
    Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio 45229 3039, USA
    Arthritis Rheum 48:218-26. 2003
    ..All patients had been participants in an initial randomized efficacy and safety trial of etanercept...
  5. doi request reprint Adalimumab with or without methotrexate in juvenile rheumatoid arthritis
    Daniel J Lovell
    Cincinnati Children s Hospital Medical Center, Division of Rheumatology, Location E, Rm 2 129, MLC 4010, 3333 Burnet Ave, Cincinnati, OH 45229 3039, USA
    N Engl J Med 359:810-20. 2008
    ..We evaluated the efficacy and safety of adalimumab, a fully human monoclonal anti-TNF antibody, in children with polyarticular-course juvenile rheumatoid arthritis...
  6. ncbi request reprint Biologic agents for the treatment of juvenile rheumatoid arthritis: current status
    Ruy Carrasco
    Levinson Chair of Pediatric Rheumatology, Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio 45229, USA
    Paediatr Drugs 6:137-46. 2004
    ..Randomized trials are ongoing to better define both the efficacy and safety of these novel treatments for children with JRA and other rheumatic diseases...
  7. doi request reprint Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis
    Daniel J Lovell
    Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio 45229, USA
    Arthritis Rheum 58:1496-504. 2008
    ..To evaluate the safety and efficacy of up to 8 years of etanercept treatment in patients with polyarticular-course juvenile rheumatoid arthritis (JRA)...
  8. pmc Measuring process of arthritis care: a proposed set of quality measures for the process of care in juvenile idiopathic arthritis
    Daniel J Lovell
    Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio 45229, USA
    Arthritis Care Res (Hoboken) 63:10-6. 2011
    ..The objective of this effort was to establish a set of QMs for the assessment of the process of care in juvenile idiopathic arthritis (JIA)...
  9. ncbi request reprint A randomized controlled trial of calcium supplementation to increase bone mineral density in children with juvenile rheumatoid arthritis
    Daniel J Lovell
    Cincinnati Children s Hospital Medical Center, William S Rowe Division of Rheumatology ML4010, 3333 Burnet Avenue, Cincinnati, OH 45229, USA
    Arthritis Rheum 54:2235-42. 2006
    ....
  10. ncbi request reprint Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal-onset multisystem inflammatory disease
    Daniel J Lovell
    Cincinnati Children s Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio 45229, USA
    Arthritis Rheum 52:1283-6. 2005
    ..These observations suggest that IL-1 plays a critical role in the pathogenesis of this inflammatory disease, and that blockade with anakinra should be further studied as a treatment for patients with NOMID and related disorders...
  11. ncbi request reprint Pediatric clinical research
    Daniel J Lovell
    Cincinnati Children s Hospital, Cincinnati, Ohio 45229, USA
    Curr Opin Rheumatol 17:265-70. 2005
    ..This review will focus on childhood-onset systemic lupus erythematosus, juvenile idiopathic arthritis, and juvenile dermatomyositis, with special interest on strategies to improve the health-related quality of life in these conditions...
  12. ncbi request reprint Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis
    Daniel J Lovell
    Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio 45229, USA
    Arthritis Rheum 54:1987-94. 2006
    ..The goal of our study was to provide data on safety and efficacy after 4 years of etanercept treatment in patients with JRA...
  13. pmc Biochemical markers of bone turnover associated with calcium supplementation in children with juvenile rheumatoid arthritis: results of a double-blind, placebo-controlled intervention trial
    Ruy Carrasco
    Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio, USA
    Arthritis Rheum 58:3932-40. 2008
    ....
  14. doi request reprint Effects of long-term etanercept treatment on growth in children with selected categories of juvenile idiopathic arthritis
    Edward H Giannini
    Pediatric Rheumatology, Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio 45229, USA
    Arthritis Rheum 62:3259-64. 2010
    ..To evaluate the effects of long-term etanercept treatment, with or without methotrexate, on growth in children with selected categories of juvenile idiopathic arthritis (JIA)...
  15. pmc Changes in pain coping, catastrophizing, and coping efficacy after cognitive-behavioral therapy in children and adolescents with juvenile fibromyalgia
    Susmita Kashikar-Zuck
    Division of Behavioral Medicine and Clinical Psychology, Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio 45229, USA
    J Pain 14:492-501. 2013
    ..Future directions for understanding mechanisms of CBT effectiveness in adolescents with chronic pain are discussed...
  16. pmc Long-term safety, efficacy, and quality of life in patients with juvenile idiopathic arthritis treated with intravenous abatacept for up to seven years
    Daniel J Lovell
    Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio
    Arthritis Rheumatol 67:2759-70. 2015
    ..The aim of this study was to present the safety, efficacy, and patient-reported outcomes of abatacept treatment (10 mg/kg every 4 weeks) during the LTE phase, for up to 7 years of followup...
  17. pmc Determinants of health-related quality of life in children newly diagnosed with juvenile idiopathic arthritis
    Michael Seid
    Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio
    Arthritis Care Res (Hoboken) 66:263-9. 2014
    ....
  18. ncbi request reprint Gastrointestinal symptoms and their association with health-related quality of life of children with juvenile rheumatoid arthritis: validation of a gastrointestinal symptom questionnaire
    Hermine I Brunner
    Division of Rheumatology E 4010, Cincinnati Children s Hospital Medical Center, University of Cincinnati, 3333 Burnet Avenue, Cincinnati, OH 45229 3039, USA
    J Clin Rheumatol 11:194-204. 2005
    ....
  19. ncbi request reprint Minimal clinically important differences of the childhood health assessment questionnaire
    Hermine I Brunner
    Division of Rheumatology, Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio 45229 3039, USA
    J Rheumatol 32:150-61. 2005
    ..125. We estimated minimal clinically important differences (MCID) of the CHAQ for worsening and improvement that were actually experienced by children with JRA using patient, parent, and clinical perspectives...
  20. ncbi request reprint Feasibility and construct validity of the parent willingness-to-pay technique for children with juvenile idiopathic arthritis
    Andrea C Barron
    Cincinnati Children s Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio 45229 3039, USA
    Arthritis Rheum 51:899-908. 2004
    ..To assess the feasibility and construct validity of the willingness-to-pay (WTP) technique for measuring health care preferences in families of children with juvenile idiopathic arthritis (JIA)...
  21. pmc High Levels of Decisional Conflict and Decision Regret When Making Decisions About Biologics
    Ellen A Lipstein
    Division of Adolescent and Transition Medicine, Department of Pediatrics Department of Pediatrics, James M Anderson Center for Health Systems Excellence, Cincinnati Children s Hospital Medical Center University of Cincinnati College of Medicine Division of Rheumatology Division of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Cincinnati Children s Hospital Medical Center, Cincinnati Division of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Nationwide Children s Hospital The Ohio State College of Medicine Division of Rheumatology, Department of Pediatrics, Nationwide Children s Hospital, Columbus Division of Biostatistics and Epidemiology, Department of Pediatrics, Cincinnati Children s Hospital Medical Center, Cincinnati, OH
    J Pediatr Gastroenterol Nutr 63:e176-e181. 2016
    ..The aim of the study was to understand the association between parents' perceptions of the decision process and the decision outcomes in decisions about the use of biologics in pediatric chronic conditions...
  22. pmc Cognitive behavioral therapy for the treatment of juvenile fibromyalgia: a multisite, single-blind, randomized, controlled clinical trial
    Susmita Kashikar-Zuck
    Cincinnati Children s Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati, Ohio 45229, USA
    Arthritis Rheum 64:297-305. 2012
    ....
  23. pmc Disease control and health-related quality of life in juvenile idiopathic arthritis
    Michael Seid
    Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio 45229 3039, USA
    Arthritis Rheum 61:393-9. 2009
    ....
  24. ncbi request reprint Preliminary definition of disease flare in juvenile rheumatoid arthritis
    Hermine I Brunner
    William S Rowe Division of Rheumatology, Cincinnati Children s Hospital Medical Center, OH 45229, USA
    J Rheumatol 29:1058-64. 2002
    ..To develop preliminary criteria for defining disease flare in patients with polyarticular-course juvenile rheumatoid arthritis (JRA)...
  25. pmc Making decisions about chronic disease treatment: a comparison of parents and their adolescent children
    Ellen A Lipstein
    Center for Innovation in Chronic Disease Care, Division of Adolescent Medicine, Cincinnati Children s Hospital Medical Center, Cincinnati, OH, USA
    Health Expect 19:716-26. 2016
    ..To compare factors considered by parents to those considered by adolescents making decisions about chronic disease treatments...
  26. pmc Physicians' Perceptions of Shared Decision Making in Chronic Disease and Its Barriers and Facilitators
    Cassandra M Dodds
    Center for Innovation in Chronic Disease Care, Division of Adolescent and Transition Medicine, Cincinnati Children s Hospital Medical Center, Cincinnati, OH
    J Pediatr 171:307-9.e1-2. 2016
    ..At the same time, they perceived few barriers, other than insurance limitations, to using SDM. ..
  27. doi request reprint Parents' information needs in tumor necrosis factor-α inhibitor treatment decisions
    Ellen A Lipstein
    Cincinnati Children s Hospital Medical Center, Cincinnati, OH 45229, USA
    J Pediatr Gastroenterol Nutr 56:244-50. 2013
    ..The aim of the study was to describe parents' experiences and the information used when making decisions about tumor necrosis factor-α inhibitor (TNFαi) treatment...
  28. ncbi request reprint Update on treatment of arthritis in children: new treatments, new goals
    Daniel J Lovell
    Children s Hospital Medical Center, Location E, Room 2 129, 3333 Burnet Avenue, Cincinnati, Ohio 45229, USA
    Bull NYU Hosp Jt Dis 64:72-6. 2006
    ..In systemic JIA approximately 50% respond to anti-TNF agents, but in many the response is not sustained. Openlabel studies have shown promising results for biologic therapies that block interleukins 1 and 6 in systemic JIA...
  29. pmc Relationship between school absenteeism and depressive symptoms among adolescents with juvenile fibromyalgia
    Susmita Kashikar-Zuck
    Division of Behavioral Medicine and Clinical Psychology, Cincinnati Children s Hospital Medical Center, Cincinnati, OH 45229, USA
    J Pediatr Psychol 35:996-1004. 2010
    ..To describe school absences in adolescents with Juvenile Primary Fibromyalgia Syndrome (JPFS) and examine the relationship between school absenteeism, pain, psychiatric symptoms, and maternal pain history...
  30. pmc Actigraphy-based physical activity monitoring in adolescents with juvenile primary fibromyalgia syndrome
    Susmita Kashikar-Zuck
    Division of Behavioral Medicine and Clinical Psychology, Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio, USA
    J Pain 11:885-93. 2010
    ..Preliminary findings suggest that further study of factors that predict perceived and actual physical functioning in JPFS is warranted...
  31. doi request reprint Lack of Concordance in Inter-Rater Scoring of the Provider's Global Assessment of Children with Juvenile Idiopathic Arthritis with Low Disease Activity
    Janalee Taylor
    Cincinnati Children s Hospital Medical Center, Division of Rheumatology, Cincinnati, OH
    Arthritis Care Res (Hoboken) . 2017
    ....
  32. pmc Monocyte MicroRNA Expression in Active Systemic Juvenile Idiopathic Arthritis Implicates MicroRNA-125a-5p in Polarized Monocyte Phenotypes
    Grant S Schulert
    Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio
    Arthritis Rheumatol 68:2300-13. 2016
    ..MicroRNAs are critical regulators of monocyte polarization and function, but cellular microRNAs in systemic JIA have not been examined systematically...
  33. pmc Parents' information needs and influential factors when making decisions about TNF-α inhibitors
    Ellen A Lipstein
    Division of Adolescent and Transition Medicine, Cincinnati Children s Hospital Medical Center, 3333 Burnet Ave, Cincinnati, OH, 45229, USA
    Pediatr Rheumatol Online J 14:53. 2016
    ..The objective of this study was to describe parents' information needs and the influences on their decision making about treatment with TNF-α inhibitors...
  34. doi request reprint Enhancing crossover trial design for rare diseases: limiting ineffective exposure and increasing study power by enabling patient choice to escape early
    Bin Huang
    Cincinnati Children s Hospital Medical Center, Cincinnati, OH 45229, USA Electronic address
    Contemp Clin Trials 38:204-12. 2014
    ..The familial Mediterranean fever (FMF) rilonacept trial (Hashkes et al., Ann Intern Med 2012;157:533-41) demonstrates a novel crossover design by enabling patient choice to early escape for rare disease...
  35. doi request reprint A52: the impact of adalimumab on growth in patients with juvenile idiopathic arthritis
    Daniel J Lovell
    Cincinnati Children s Hospital Medical Center, Cincinnati, OH
    Arthritis Rheumatol 66:S77-8. 2014
    ..The purpose of this post hoc analysis is to describe growth parameters in pts with JIA treated with ADA in a clinical trial setting...
  36. ncbi request reprint Association between lack of angiogenic response in muscle tissue and high expression of angiostatic ELR-negative CXC chemokines in patients with juvenile dermatomyositis: possible link to vasculopathy
    Ndate Fall
    Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio 45229, USA
    Arthritis Rheum 52:3175-80. 2005
    ..To investigate the relationship between the vasculopathy of juvenile dermatomyositis (juvenile DM) and the balance between the angiostatic ELR- and angiogenic ELR+ CXC chemokines in the muscle of patients with the disease...
  37. ncbi request reprint Health of children with chronic arthritis: relationship of different measures and the quality of parent proxy reporting
    Hermine I Brunner
    Cincinnati Children s Hospital Medical Center, University of Cincinnati, Cincinnati, OH 45229 3039, USA
    Arthritis Rheum 51:763-73. 2004
    ..To evaluate whether HRQOL scores vary as a function of disability status beyond chance. To assess the quality of the parent proxy report for HRQOL as compared with disability, pain, and well-being...
  38. doi request reprint A147: engaging patients and families in the pediatric rheumatology care and outcomes improvement network
    Esi Morgan Dewitt
    Cincinnati Children s Hospital Medical Center, Cincinnati, OH
    Arthritis Rheumatol 66:S190. 2014
    ..PR-COIN aims to grow this initiative to bring care providers, patients and family members together as co-producers in improving care and outcomes...
  39. doi request reprint A169: cumulative long-term safety, efficacy and patient-reported outcomes in children with juvenile idiopathic arthritis treated with intravenous abatacept: up to 7 years of treatment
    Daniel J Lovell
    Cincinnati Children s Hospital Medical Center, Cincinnati, OH
    Arthritis Rheumatol 66:S218-9. 2014
    ..Here, we report efficacy, safety and pt-reported outcomes from the open-label, long-term extension (LTE) of AWAKEN, with up to 7 years of follow-up...
  40. doi request reprint A20: Understanding the Use and Biology of TNF Therapy in JIA-Clinical Outcomes
    Daniel J Lovell
    Cincinnati Children s Hospital Medical Center, Cincinnati, OH
    Arthritis Rheumatol 66:S31-2. 2014
    ..The aims of this study were to determine the frequency, timing and predictors of flare upon withdrawal of anti-TNF in PF-JIA in CID...
  41. doi request reprint Juvenile dermatomyositis: correlation of MRI at presentation with clinical outcome
    Patricia E Ladd
    Department of Pediatric Radiology, Cincinnati Children s Hospital Medical Center, OH 45229, USA
    AJR Am J Roentgenol 197:W153-8. 2011
    ..The purpose of our study is to determine whether initial MRI findings in the pelvis and thighs in children with JDMS can predict clinical disease course...
  42. doi request reprint Five cases of anti-tumor necrosis factor alpha-induced psoriasis presenting with severe scalp involvement in children
    Marissa J Perman
    Division of Dermatology, College of Medicine, University of Cincinnati and Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio, USA
    Pediatr Dermatol 29:454-9. 2012
    ..We hope that clinicians caring for patients receiving anti-TNF-α agents will consider psoriasis from the onset of cutaneous symptoms and institute appropriate therapy or referral...
  43. ncbi request reprint A randomized clinical trial of dietary calcium to improve bone accretion in children with juvenile rheumatoid arthritis
    Lori J Stark
    Division of Behavioral Medicine and Clinical Psychology, Cincinnati Children s Hospital Medical Center University of Cincinnati College of Medicine, OH 45229, USA
    J Pediatr 148:501-7. 2006
    ..To examine a behavioral intervention (BI) to increase calcium intake in children with juvenile rheumatoid arthritis (JRA) on calcium intake and bone mass 6 and 12 months after treatment...
  44. ncbi request reprint Prevention of osteoporosis: a randomized clinical trial to increase calcium intake in children with juvenile rheumatoid arthritis
    Lori J Stark
    Cincinnati Children s Hospital Medical Center, 3333 Burnet Avenue, Division of Psychology, Sec 4, Cincinnati, Ohio 45229, USA
    J Pediatr Psychol 30:377-86. 2005
    ..To test the efficacy of a behavioral intervention (BI) compared to an enhanced standard of care (ESC) dietary counseling on increasing dietary calcium (Ca) intake in children with juvenile rheumatoid arthritis (JRA)...
  45. ncbi request reprint Advanced therapy for juvenile arthritis
    Kevin J Murray
    Paediatric Rheumatology Unit, Great Ormond St Hospital for Children, London WC1N 3JH, UK
    Best Pract Res Clin Rheumatol 16:361-78. 2002
    ....
  46. doi request reprint Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial
    Nicolino Ruperto
    IRCCS G Gaslini, PRINTO, Genoa, Italy
    Lancet 372:383-91. 2008
    ..We aimed to assess the safety and efficacy of abatacept, a selective T-cell costimulation modulator, in children with juvenile idiopathic arthritis who had failed previous treatments...
  47. pmc De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases
    Ivona Aksentijevich
    National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, Maryland 20892, USA
    Arthritis Rheum 46:3340-8. 2002
    ....
  48. ncbi request reprint Health status of patients with juvenile rheumatoid arthritis at 1 and 5 years after diagnosis
    Suzanne L Bowyer
    Pediatric Rheumatology Divisions, Indiana University, Indianapolis, Indiana, USA
    J Rheumatol 30:394-400. 2003
    ..To describe the health and functional status of children with juvenile rheumatoid arthritis (JRA) diagnosed in the early 1990s...
  49. ncbi request reprint Immunosuppressants, infection, and inflammation
    Daniel J Lovell
    Division Immunologic Infectious Disease, Children s Hospital of Philadelphia, PA 19104, USA
    Clin Immunol 113:137-9. 2004
  50. ncbi request reprint A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis
    Nicolino Ruperto
    IRCCS, Istituto G Gaslini, Genoa, Italy
    Arthritis Rheum 56:3096-106. 2007
    ..To evaluate the safety and efficacy of infliximab in the treatment of juvenile rheumatoid arthritis (JRA)...
  51. ncbi request reprint The Pediatric Rheumatology International Trials Organization criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus: prospective validation of the disease activity core set
    Nicolino Ruperto
    Pediatric Rheumatology International Trials Organization PRINTO, IRCCS G Gaslini, Universita di Genova, Pediatria II Reumatologia, Largo Gaslini, Genoa, Italy
    Arthritis Rheum 52:2854-64. 2005
    ..To validate and promulgate a core set of outcome measures for the evaluation of response to treatment in patients with juvenile systemic lupus erythematosus (SLE)...
  52. ncbi request reprint Evaluation of the comparative efficacy and tolerability of rofecoxib and naproxen in children and adolescents with juvenile rheumatoid arthritis: a 12-week randomized controlled clinical trial with a 52-week open-label extension
    Andreas Reiff
    Children s Hospital Los Angeles, Los Angeles, CA, USA
    J Rheumatol 33:985-95. 2006
    ..To compare the safety and efficacy of rofecoxib* to naproxen for the treatment of juvenile rheumatoid arthritis (JRA)...
  53. ncbi request reprint Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis
    Nicolino Ruperto
    IRCCS G Gasalini, Pediatria II, Genova, Italy
    Rheumatology (Oxford) 42:1452-9. 2003
    ..To identify preliminary core sets of outcome variables for disease activity and damage assessment in juvenile systemic lupus erythematosus (JSLE) and juvenile dermatomyositis (JDM)...
  54. doi request reprint The provisional Paediatric Rheumatology International Trials Organisation/American College of Rheumatology/European League Against Rheumatism Disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: a prospective va
    Nicolino Ruperto
    IRCCS G Gaslini, Genoa, Italy
    Arthritis Rheum 59:4-13. 2008
    ..To validate a core set of outcome measures for the evaluation of response to treatment in patients with juvenile dermatomyositis (DM)...
  55. doi request reprint Performing trials in children with rheumatic diseases: comment on the editorial by Lehman
    Nicolino Ruperto
    Arthritis Rheum 58:1201-2; author reply 1203. 2008

Research Grants1

  1. CLINICAL TRAILS IN PEDIATRIC RHEUMATOLOGY
    Daniel Lovell; Fiscal Year: 2004
    ..2. Determine the long-term efficacy and safety of these treatment regimens in sJRA. ..